Stem Cell Therapy Restores Mobility in Young Child

A three-year-old child, Tobi Maginnis, who was expected to face paralysis due to spina bifida, has regained the ability to walk following a stem cell treatment administered during fetal surgery. This development marks a significant advancement in treating spina bifida, a congenital disorder affecting approximately 500 infants annually in the UK and between 8,100 to 11,900 individuals in England and Wales. The treatment, part of a world-first clinical trial conducted by the University of California, Davis Children’s Hospital, has generated renewed hope for those affected by the condition.

Spina bifida is a neural tube defect that occurs when the spinal cord fails to develop properly during early pregnancy. The most severe form, myelomeningocele, can result in lower limb paralysis, bladder and bowel dysfunction, and complications such as hydrocephalus. While fetal surgery to correct the defect has been available for decades, approximately 60% of children still face mobility challenges post-procedure. Researchers have explored innovative therapies, including stem cell interventions, to improve treatment outcomes.

The CuRe Trial, led by fetal and neonatal surgeon Dr. Diana Farmer, integrates traditional fetal surgery with the application of placenta-derived mesenchymal stem cells (PMSCs) to the exposed spinal cord of fetuses diagnosed with myelomeningocele. The procedure, performed between 24-25 weeks of gestation, involves placing a stem cell patch over the spinal defect to stimulate tissue regeneration and repair.

Participants: Six pregnant women participated in the initial Phase 1/2a trial, with plans to expand to 35 patients.

Procedure: Surgeons made a small abdominal incision, applied the PMSC patch to the fetal spinal cord, and closed the incision. All newborns were delivered via cesarean section at approximately 34 weeks gestation.

Safety: No complications such as infections, cerebrospinal fluid leaks, or tumor growth were reported. MRI scans confirmed the reversal of hindbrain herniation, a complication linked to spina bifida, in all cases.

Tobi Maginnis, one of the six trial participants, is now walking and running, defying initial predictions of wheelchair dependence. His parents described him as “full of energy,” with no signs of the condition’s typical complications. The treatment appears to reverse hindbrain herniation, a critical factor in preventing long-term neurological damage. Dr. Farmer noted that the results “pave the way for lots of potential new treatments for spina bifida and other birth defects.”

The trial’s long-term success will be evaluated through follow-ups over several years to assess functional outcomes such as walking ability, bladder and bowel control, and cognitive development. The CuRe Trial builds on decades of research, including successful experiments in sheep models and the Nobel Prize-winning research by Shinya Yamanaka. Similar efforts, such as Intermountain Health’s fetoscopic spina bifida surgery in Utah, aim to reduce complications and improve fetal outcomes.

While the trial’s results are promising, experts caution against overinterpretation. Dr. Clare Whitehead, a fetal-medicine specialist, emphasized that “positive results in small studies don’t always translate to benefits in larger populations.” The trial’s next phase will focus on expanding enrollment and long-term follow-up to confirm the treatment’s efficacy and safety.

The CuRe Trial represents a transformative step in the treatment of spina bifida, offering hope to families facing the condition’s lifelong challenges. As research continues, the integration of stem cell therapy with fetal surgery may redefine the standard of care, potentially improving mobility, neurological outcomes, and quality of life for thousands of children worldwide.